This biweekly video recap in Vaccines covers regulatory actions, clinical progress, real-world pilot programs, and platform partnerships across global markets.
🎯 Watch Our Video Summary Capturing Vaccines News from the Last Two Weeks
Dive deeper
🗓️ Explore weekly details and sources
- Week 23–29 January 2026
- Week 30 January–6 February 2026
📚 See the full Vaccines archive on our research hub page.
Top Stories Covered in This Video
Chapters
0:00 Introduction
0:09 EU expands Arexvy indication to adults 18+ across EU/EEA
0:33 CEPI–SK bioscience–MSD 30 million dollar program to enhance Zaire ebolavirus vaccine manufacturing and stability
0:53 Mexico grants patent for Anixa α-lactalbumin breast cancer vaccine technology
1:14 SK bioscience initiates international Phase 1–2 trial of multivalent sarbecovirus vaccine GBP511 in Australia
1:35 Arcturus completes Phase 1 for sa-mRNA influenza vaccine candidate ARCT-2304
1:56 FDA grants orphan drug designation to TuHURA Biosciences IFx-2.0 in cutaneous melanoma
2:19 Brazil launches pilot vaccination with single-shot chikungunya vaccine IXCHIQ via Instituto Butantan and Ministry of Health
2:45 Invivyd aligns with FDA on LIBERTY Phase 3 design for VYD2311 comparing mAb prophylaxis with mRNA COVID vaccines
3:19 How to reach us
Transcript
Welcome to the latest edition of Vaccines Research Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.
First, the European Commission has approved GSK’s adjuvanted RSV vaccine Arexvy for adults 18 and older across the EU and EEA, expanding beyond the prior authorizations for adults 60 and older, then for adults 50 to 59 at increased risk, with the company pursuing similar expansions in the United States and Japan.
Next, CEPI has committed 30 million dollars in partnership with SK bioscience, MSD, and Hilleman Labs to enhance manufacturing, formulation, and stability for a Zaire ebolavirus vaccine, aiming to improve yields and reduce ultra-cold-chain requirements. In Mexico,
Anixa Biosciences has received a Notice of Allowance for a composition-of-matter patent covering an alpha-lactalbumin breast cancer vaccine technology licensed from Cleveland Clinic, building on Phase 1 immune-response signals and a focus on triple-negative breast cancer.
SK bioscience has initiated an international Phase 1 slash 2 clinical trial in Australia for GBP511, a multivalent nanoparticle vaccine candidate designed to target the sarbecovirus family, with a planned comparative arm including Comirnaty and enrollment of healthy adults.
Arcturus Therapeutics has completed a Phase 1, first-in-human study of ARCT-2304, its self-amplifying mRNA influenza vaccine candidate, part of a BARDA-supported program that compared doses against licensed influenza vaccines, with next steps to be outlined by the company.
In oncology, the FDA has granted orphan drug designation to TuHURA Biosciences’ IFx-2.0 for stage IIB through IV cutaneous melanoma, following early Phase 1 safety and activity signals without dose-limiting toxicities, while a separate Phase 3 trial in Merkel cell carcinoma proceeds.
In Brazil, Instituto Butantan and the Ministry of Health have launched a pilot vaccination campaign using Valneva’s single-shot chikungunya vaccine IXCHIQ for adults 18 to 59 in ten municipalities, with up to 500,000 donated doses and a target of 20 to 40 percent coverage to generate real-world effectiveness and safety data.
Finally, Invivyd has aligned with the FDA on the LIBERTY Phase 3 design for VYD2311, a monoclonal antibody for COVID-19 prophylaxis, which will compare VYD2311 with mRNA COVID vaccines in about 210 participants, include options for co-administration, and incorporate monitoring for myocarditis and pericarditis, while the DECLARATION Phase 3 prevention trial continues in parallel. Why it matters, a broader Arexvy label moves adult RSV prevention from high-risk niches toward population-level immunization.
Stay ahead in Vaccines Research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!
Why it matters
- Adult RSV prevention: EU’s broader Arexvy label shifts RSV from high-risk niches toward population-level adult immunization.
- Outbreak readiness: CEPI’s Ebola manufacturing push targets stability and access in low-resource settings.
- Broad-spectrum bets: Sarbecovirus and sa-mRNA programs reflect platform strategies for future respiratory threats.
- Oncology vaccines: Orphan designation and new IP positions keep cancer-vaccine pipelines advancing despite early-stage data.
- Real-world evidence: Brazil’s chikungunya pilot emphasizes effectiveness and programmatic feasibility, not just trial efficacy.
🗓️ Explore weekly details and sources
- Week 23–29 January 2026
- Week 30 January–6 February 2026
📚 See the full Vaccines archive on our research hub page.
FAQ
What exactly did the EU approve for Arexvy?
Arexvy now has an EU/EEA indication for adults 18+, expanding beyond prior older-adult authorizations. GSK is pursuing additional markets. [1]
How will the CEPI–SK bioscience–MSD Ebola project help access?
Partners aim to improve yields and temperature robustness for the Zaire ebolavirus vaccine, which could ease cold-chain constraints. [2]
What protection does Anixa’s new patent provide?
Mexico granted a Notice of Allowance covering composition-of-matter claims for an α-lactalbumin breast cancer vaccine technology licensed from Cleveland Clinic. [3]
What is unique about SK bioscience’s GBP511 trial?
It evaluates a multivalent sarbecovirus nanoparticle vaccine with comparisons to Comirnaty, targeting family-level protection. Details are early stage. [4]
What did FDA’s ODD mean for IFx-2.0?
Orphan status in cutaneous melanoma supports development incentives; efficacy details are limited to early Phase 1 signals. [6]
What will Brazil’s IXCHIQ pilot measure?
Effectiveness and safety in real-world use across selected municipalities, with up to 500,000 doses and 20–40% coverage goals. [7]
Entities / Keywords
Arexvy, GSK, RSV; CEPI, SK bioscience, MSD, Ebola, Zaire ebolavirus; Anixa Biosciences, α-lactalbumin, Cleveland Clinic, TNBC; SK bioscience GBP511, sarbecovirus, nanoparticle vaccine, Comirnaty; Arcturus Therapeutics, ARCT-2304, sa-mRNA, BARDA; TuHURA Biosciences, IFx-2.0, orphan drug designation, melanoma; Valneva, Instituto Butantan, IXCHIQ, chikungunya; Invivyd, VYD2311, LIBERTY, DECLARATION, myocarditis.
References
https://www.clinicaltrialsarena.com/news/invivyd-fda-advice-liberty-trial/